Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug free myelofibrosis patients from frequent blood transfusions?

NCT ID NCT04717414

Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 3 study tests whether the drug luspatercept can help people with myelofibrosis-related anemia become independent of red blood cell transfusions. Participants are adults with myelofibrosis who are already taking a JAK inhibitor and need regular transfusions. The study compares luspatercept to a placebo to see if it reduces or eliminates the need for transfusions over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a drug called luspatercept (ACE-536) given as a shot under the skin
What this could lead to
If it works, luspatercept could help people with myelofibrosis need fewer blood transfusions, improving their quality of life.
What could go wrong
This is a phase 3 trial, but the drug may not work better than placebo, and side effects are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

313 people

The number who actually took part.

Started

Feb 2021

Expected to finish

Aug 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Subjects must satisfy the following criteria to be randomized in the study: Inclusion Criteria \- Subject is ≥18 years of age at the time of signing the ICF. * Subject has a diagnosis of PMF according to the 2016 World Health Organization (WHO) criteria or diagnosis of post-ET or post-PV MF according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report. * Subject is requiring RBC transfusions as defined as:. i) Average RBC-transfusion frequency: 4 to 12 RBC units/12 weeks immediately up to randomization. There must be no interval \> 6 weeks (42 days) without ≥ 1 RBC transfusion. ii) RBC transfusions are scored in determining eligibility when given for treatment of:. A. Symptomatic (ie, fatigue or shortness of breath) anemia with a pretransfusion Hgb ≤ 9.5 g/dL or. B. Asymptomatic anemia with a pretransfusion Hgb ≤ 7 g/dL. iii) RBC transfusions given for worsening of anemia due to bleeding or infections are not scored in determining eligibility. \- Subjects on continuous (eg, absent of dose interruptions lasting ≥ 2 consecutive weeks) JAK2 inhibitor therapy as approved in the country of the study site for the treatment for MPN-associated MF as part of their standard-of-care therapy for at least 32 weeks, on stable daily dose for at least 16 weeks immediately up to the date of randomization and anticipated to be on a stable daily dose of that JAK2 inhibitor for at least 24 weeks after randomization. * Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2. * A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP)participating in the study must:. i) Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the subject practices true abstinence\* from heterosexual contact. ii) Either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception\*\* without interruption, 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy. \- Male subjects must: Practice true abstinence\* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential\*\* while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy. i) True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject. \[Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.\]. ii) Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Combined (estrogen and progestogen containing) hormonal contraception: Oral, Intravaginal, Transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral, Injectable hormonal contraception, Implantable hormonal contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence. * Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. * Subject is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device. Exclusion Criteria * The presence of any of the following will exclude a subject from randomization:. * Subject with anemia from cause other than MPN-associated MForJAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration). * Subject use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids or other drugs with potential effects on hematopoiesis ≤ 8 weeks immediately up to the date of randomization. i) Systemic corticosteroids are permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to randomization. ii) Iron chelation therapy (ICT) is permitted providing the subject is receiving a stable dose for the 8 weeks immediately up to randomization. \- Subject with any of the following laboratory abnormalities at screening:. i) Neutrophils: \< 1 x 10\^9/L. ii) White blood count (WBC): \> 100 x 10\^9/L. iii) Platelets: the lowest allowable level as approved for the concomitant JAK2 inhibitor but not \< 25 x 10\^9/L or \> 1000 x 10\^9/L. iv) Peripheral blood myeloblasts:\> 5%. v) Estimated glomerular filtration rate:\< 30 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease \[MDRD\] formula) or nephrotic subjects (eg, urine albumin-to-creatinine ratio \> 3500 mg/g). vi) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):\> 3.0 x upper limit of normal (ULN). vii) Direct bilirubin: ≥ 2 x ULN. A. Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis). * Subject with uncontrolled hypertension, defined as repeated elevations of systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, that is not resolved at the time of randomization. * Subject with prior history of malignancies, other than disease under study, unless the subject has been free of the disease for ≥ 3 years. However, subject with the following history/concurrent conditions is allowed:. i) Basal or squamous cell carcinoma of the skin. ii) Carcinoma in situ of the cervix. iii) Carcinoma in situ of the breast. iv) Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \[TNM\] clinical staging system). * Subject with prior hematopoietic cell transplant or subject anticipated to receive a hematopoietic cell transplant during the 24 weeks from the date of randomization. 7. Subject with stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months immediately up to the date of randomization. * Subject with major surgery within 2 months up to the date of randomization. Subject must have completely recovered from any previous surgery immediately up to the date of randomization. * Subject with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 6 months prior to the date of randomization. * Subject with inadequately controlled heart disease and/or have a known left ventricular ejection fraction \< 35%. * Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment). * Subject with known human immunodeficiency virus (HIV), evidence of active Hepatitis B (HepB) as demonstrated by the presence of Hepatitis B surface antigen (HBsAg) and/or positive for Hepatitis B virus DNA (HBVDNA-positive), and/or evidence of active Hepatitis C (HepC) as demonstrated by a positive Hepatitis C virus RNA (HCV-RNA) test of sufficient sensitivity. * Subject with prior therapy of luspatercept or sotatercept. * Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product. * Pregnant or breastfeeding females. * Subject participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, immediately up to the date of randomization. * Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study or places the subject at unacceptable risk if he/she were to participate in the study. 18.Subject with any condition or concomitant medication that confounds the ability to interpret data from the study. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Myelofibrosis Myeloproliferative disorders Post-polycythemia vera myelofibrosis Primary myelofibrosis

Contacts and locations

Locations

  • A.O.U. Maggiore della Carit

    Novara, 28100, Italy

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15224, United States

  • Aomori Prefectural Central Hospital

    Aomori, 030-8553, Japan

  • Asan Medical Center

    Seoul, 5505, South Korea

  • Asst Spedali Civili Di Brescia

    Brescia, 25123, Italy

  • Attikon University General Hospital

    Athens, 12464, Greece

  • Azienda Ospedaliera Di Padova

    Padova, 35128, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, 50134, Italy

  • Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico

    Catania, 95123, Italy

  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi

    Bologna, 40138, Italy

  • Azienda Policlinico Universitario Umberto I

    Roma, 00100, Italy

  • Beijing Peking Union Medical College Hospital

    Beijing, 100730, China

  • CHU La Miletrie

    Poitiers, 86021, France

  • CHU de Nice Archet I

    Nice, 06202, France

  • Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau

    Nîmes, 30029, France

  • Centro Ricerche Cliniche di Verona S.r.l.

    Verona, 37134, Italy

  • Chonnam National University Hwasun Hospital

    Hwasun-Gun, 58128, South Korea

  • Chu De Grenoble

    Grenoble, 38043, France

  • Churchhill Hospital

    Oxford, OX3 7LI, United Kingdom

  • Cliniques Universitaires UCL de Mont-Godine

    Yvoir, 5530, Belgium

  • Complejo Hospitalario Universitario De Santiago

    Santiago de Compostela, 15706, Spain

  • Cork University Hospital

    Cork, T12 DFK4, Ireland

  • Evangelismos General Hospital of Athens

    Athens, 10676, Greece

  • Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico

    Milan, 20122, Italy

  • Georgios Papanikolaou General Hospital of Thessaloniki

    Thessaloniki, 57010, Greece

  • Gosford Hospital

    Gosford, 2250, Australia

  • Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli

    Reggio Calabria, 89124, Italy

  • Groupe Hospitalier Sud Hopital Haut Leveque USN

    Pessac, 33604, France

  • Guangdong General Hospital

    Guangzhou, 510030, China

  • Hadassah Medical Organization

    Jerusalem, 91120, Israel

  • Heart of England NHS Foundation Trust

    Birmingham, B9 5SS, United Kingdom

  • Hopital Saint Louis

    Paris, 75475, France

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario De Valencia

    Valencia, 46010, Spain

  • Hospital Italiano de Buenos Aires

    Buenos Aires, C1199ABB, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, B1900AX, Argentina

  • Hospital Universitari Germans Trias i Pujol ICO Badalona

    Barcelona, 08916, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, 28041, Spain

  • Hospital Universitario De Gran Canaria Dr. Negrin

    Las Palmas de Gran Canaria, 35012, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • IC La Serena Research

    La Serena, Coquimbo Region, 1720430, Chile

  • ICANS Institut de cancerologie Strasbourg Europe

    Strasbourg, 67200, France

  • IRCCS - Istituto Romagnolo per lo Studio Dei Tumori "Dino Amadori" (IRST)

    Meldola (fc), Fc, 47014, Italy

  • Johannes Wiesling Klinikum Minden

    Minden, 32429, Germany

  • John Theurer Cancer Center

    Hackensack, New Jersey, 07601-2191, United States

  • Kameda General Hospital

    Kamogawa, 296-8602, Japan

  • Kindai University Hospital- Osakasayama Campus

    Sayama, Osaka, 5898511, Japan

  • Krankenhaus der Elisabethinen Linz, I Interne Abteilung

    Linz, 4020, Austria

  • Kyungpook National University Hospital

    Daegu, 700-721, South Korea

  • Local Institution - 108

    St Louis, Missouri, 63110, United States

  • Local Institution - 110

    Los Angeles, California, 90095, United States

  • Local Institution - 112

    Chicago, Illinois, 60612, United States

  • Local Institution - 114

    Ann Arbor, Michigan, 48109, United States

  • Local Institution - 119

    Salt Lake City, Utah, 84112, United States

  • Local Institution - 124

    Lexington, Kentucky, 40536-0293, United States

  • Local Institution - 130

    Knoxville, Tennessee, 37920, United States

  • Local Institution - 133

    Plantation, Florida, 33322, United States

  • Local Institution - 135

    Orlando, Florida, 32804, United States

  • Local Institution - 161

    Medellín, Antioquia, 50034, Colombia

  • Local Institution - 162

    Floridablanca, Soto, 681002, Colombia

  • Local Institution - 163

    Bogotá, Distrito Capital de Bogotai, 111511, Colombia

  • Local Institution - 172

    Ciudad Autónoma de BuenosAires, Buenos Aires, C1280AEB, Argentina

  • Local Institution - 176

    Sherbrooke, Quebec, J1H5N4, Canada

  • Local Institution - 177

    Montreal, Quebec, H1T 2M4, Canada

  • Local Institution - 179

    Edmonton, Alberta, T6G 2S2, Canada

  • Local Institution - 180

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 181

    Calgary, Alberta, T2N 4N2, Canada

  • Local Institution - 183

    Vancouver, British Columbia, V6Z 2A5, Canada

  • Local Institution - 192

    Las Condes, Metropolitana de Santiago, 7560742, Chile

  • Local Institution - 193

    Santiago, 7500587, Chile

  • Local Institution - 202

    Palma de Mallorca, 7120, Spain

  • Local Institution - 208

    Granada, 18014, Spain

  • Local Institution - 245

    Terni, 05100, Italy

  • Local Institution - 246

    Napoli Campania, 80131, Italy

  • Local Institution - 248

    Pisa, 56100, Italy

  • Local Institution - 249

    Roma, 144, Italy

  • Local Institution - 250

    Ancona, 60126, Italy

  • Local Institution - 251

    Roma, 00189, Italy

  • Local Institution - 259

    Torino, 10126, Italy

  • Local Institution - 271

    Vienna, 1090, Austria

  • Local Institution - 272

    Graz, 8036, Austria

  • Local Institution - 274

    Vienna, 1140, Austria

  • Local Institution - 297

    Leipzig, 04103, Germany

  • Local Institution - 299

    Düsseldorf, 40225, Germany

  • Local Institution - 300

    Hamburg, 22081, Germany

  • Local Institution - 301

    Mannheim, 68167, Germany

  • Local Institution - 312

    Brussels, 1200, Belgium

  • Local Institution - 313

    Hasselt, 3500, Belgium

  • Local Institution - 315

    Verviers, 4800, Belgium

  • Local Institution - 316

    Roeselare, 8800, Belgium

  • Local Institution - 318

    Bruges, 8000, Belgium

  • Local Institution - 319

    Liège, 4000, Belgium

  • Local Institution - 324

    Créteil, 94010, France

  • Local Institution - 327

    Lille, 59037, France

  • Local Institution - 330

    Toulouse, 31059, France

  • Local Institution - 331

    Angers, 49033, France

  • Local Institution - 332

    Lyon, 69008, France

  • Local Institution - 333

    Clermont-Ferrand, 63000, France

  • Local Institution - 341

    Prague, 128 08, Czechia

  • Local Institution - 383

    Alexandroupoli, 08100, Greece

  • Local Institution - 386

    Athens, 11 527, Greece

  • Local Institution - 387

    Pátrai, Achaia, 264 43, Greece

  • Local Institution - 391

    Bucharest, 022328, Romania

  • Local Institution - 395

    Craiova, Dolj, 200143, Romania

  • Local Institution - 433

    Poznan, 61-696, Poland

  • Local Institution - 435

    Wroclaw, 50367, Poland

  • Local Institution - 436

    Gdansk, 80-952, Poland

  • Local Institution - 462

    Budapest, 1096, Hungary

  • Local Institution - 463

    Győr, 9023, Hungary

  • Local Institution - 500

    Moscow, 125284, Russia

  • Local Institution - 502

    Saint Petersburg, 197341, Russia

  • Local Institution - 503

    Saint Petersburg, 197022, Russia

  • Local Institution - 550

    Badaro Beirut, 11072280, Lebanon

  • Local Institution - 551

    Saida, South, 652, Lebanon

  • Local Institution - 552

    Beirut, 11-3288, Lebanon

  • Local Institution - 643

    Seongnam-si, 13620, South Korea

  • Local Institution - 647

    Seoul, 06351, South Korea

  • Local Institution - 661

    Hong Kong, 0, Hong Kong

  • Local Institution - 701

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Local Institution - 706

    Maebashi, 371-8511, Japan

  • Local Institution - 708

    Sapporo, 003-0006, Japan

  • Local Institution - 709

    Chūō, Yamanashi, 409-3898, Japan

  • Local Institution - 710

    Shinjyuku-ku, 160-0023, Japan

  • Local Institution - 713

    Bunkyō City, 113-8677, Japan

  • Local Institution - 717

    Kamakura, 247-8533, Japan

  • Local Institution - 800

    Tianjin, 300041, China

  • Local Institution - 801

    Shanghai, 200233, China

  • Local Institution - 802

    Changchun, 130021, China

  • Local Institution - 804

    Nanjing, Jiangsu, 210029, China

  • Local Institution - 809

    Shanghai, 200025, China

  • Local Institution - 810

    Zhengzhou, 0, China

  • Local Institution - 811

    Suzhou, 215006, China

  • Local Institution - 816

    Taiyuan, Shanxi, 030001, China

  • Local Institution - 818

    Nantong, Jiangsu, 226001, China

  • Local Institution - 820

    Nanchang, Jiangxi, 330006, China

  • Local Institution - 821

    Qingdao, Shandong, 0, China

  • Mater Misercordiae Hospital

    Dublin, 7, Ireland

  • Meir Medical Center

    Kfar Saba, 44281, Israel

  • Monash Medical Centre

    Clayton, Victoria, 3168, Australia

  • Mount Sinai Medical Center

    New York, New York, 10029, United States

  • NTT Medical Center Tokyo

    Shinagawa-ku, Tokyo, 141-8625, Japan

  • Nanchang University - The Second Affiliated Hospital

    Nanchang, Jiangxi, 330008, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, GD, 510515, China

  • Nottingham City Hospital

    Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

  • Ogaki Municipal Hospital

    Ōgaki, 503-8502, Japan

  • Onco Card SRL

    Brasov, 500052, Romania

  • Osaka Metropolitan university Hospital

    Osaka, 545-8586, Japan

  • Prince of Wales Hospital the Chinese University of Hong Kong

    Shatin, 0, Hong Kong

  • Prof. Dr. I. Chiricuta Institute of Oncology

    Cluj-Napoca, 400015, Romania

  • Rambam Medical Center

    Haifa, 31096, Israel

  • Royal Hobart Hospital

    Hobart, 7000, Australia

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

    Krakow, 31-501, Poland

  • Seoul National University Hospital

    Seoul, 3080, South Korea

  • Shamir Medical Center - Assaf Harofeh

    Ẕerifin, 70300, Israel

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, 6009, Australia

  • Sir Mortimer B. Davis - Jewish Genl

    Montreal, Quebec, H3T 1E2, Canada

  • Specjalistyczny Szpital im. dra Alfreda Sokolowskiego

    Wałbrzych, 58-309, Poland

  • St James Hospital

    Dublin, Dublin 8, Ireland

  • Stauferklinikum Schwab. Gmund

    Baden-Warttemberg, 73557, Germany

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Tel Aviv, 64239, Israel

  • The Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • The Catholic University of Korea Seoul - Saint Mary's Hospital

    Seoul, 06591, South Korea

  • The First Affiliated Hospital Of Harbin Medical University

    Harbin, 150081, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China

  • The Japanese Red Cross Nagasaki Genbaku Hospital

    Nagasaki, Nagasaki, 8528511, Japan

  • The Second Affiliated Hospital Of Kunming Medical University

    Kunming, Yunnan, 650101, China

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Tianjin Medical University General Hospital

    Tianjin, 300052, China

  • Tokai University Hospital

    Isehara City, Kanagawa, 259-1193, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku, 162-8666, Japan

  • Toyohashi Municipal Hospital

    Toyohashi, 441-8570, Japan

  • United Lincolnshire Hospitals NHS Trust

    Boston, PE21 9QS, United Kingdom

  • Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese

    Varese, 21100, Italy

  • Universitaetsklinikum Jena

    Jena, 07740, Germany

  • Universitario de Salamanca - Hospital Clinico

    Salamanca, 37007, Spain

  • Universitatsklinikum Halle Saale

    Halle, 06120, Germany

  • University General Hospital of Patras

    Rio Patras, 26500, Greece

  • University Hospital - London Health Sciences Centre

    London, Ontario, N6C 6B5, Canada

  • University of Miyazaki Hospital

    Miyazaki, 889-1692, Japan

  • University of Pittsburg Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Unviversitatsklinikum Aachen

    Aachen, 52074, Germany

  • Uz Leuven

    Leuven, 3000, Belgium

  • Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Lodzi

    Lodz, 93-510, Poland

  • Xiangya Hospital Central-South University

    Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.